NRG1 fusion-positive tumors: Unresectable/metastatic NRG1 fusion-positive solid tumors after prior systemic therapy.
750 mg IV Q2W. Premedicate before first 2 infusions.
Injection: 750 mg/15 mL vial
None listed.
Diarrhea (50%), Musculoskeletal Pain (43%), Fatigue (40%), Infusion Reactions (33%), Nausea (30%), Rash (30%), Dyspnea (25%), Edema (22%)
Consult the complete prescribing information for a comprehensive list of adverse reactions and their frequencies.
Not expected to interact via CYP enzymes.
Consult the full prescribing information for pregnancy-related considerations.
Refer to prescribing information for lactation guidance.
Pediatric safety and efficacy information is detailed in the full label.
Dose modifications for organ impairment are specified in the complete prescribing information.
Bispecific antibody binding HER2 and HER3, blocking NRG1 ligand binding and HER2/HER3 heterodimerization.
t½: ~10 days. Steady state by Cycle 4.
Clinical efficacy and safety data supporting the approval are available in the full prescribing information and from the clinical trials listed below.
Bizengri has FDA-approved indications across the following cancer types covered on CancerDrugEvidence:
Tumor-agnostic indication — applies across multiple solid tumor types with qualifying biomarker.
Bizengri (zenocutuzumab-zbco) is an FDA-approved oncology agent. Refer to the full prescribing information for complete indication details.
Refer to the full prescribing information for dosing schedules, administration instructions, and dose modifications.
Bispecific antibody binding HER2 and HER3, blocking NRG1 ligand binding and HER2/HER3 heterodimerization.
Diarrhea (50%), Musculoskeletal Pain (43%), Fatigue (40%), Infusion Reactions (33%), Nausea (30%), Rash (30%), Dyspnea (25%), Edema (22%) Diarrhea 50% Musculoskeletal Pain 43% Fatigue 40% Infusion Reactions 33% Nausea 30% Rash 30% Dyspnea 25% Edema 22%